Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and the population size is small.
The company has a commercial arrangement (simple discount patient access scheme). This makes lanadelumab available to the NHS with a discount. For enquiries about the patient access scheme please contact gb.commercial@takeda.com.
NHS England commissions highly specialist allergy services from highly specialist allergy centres, which includes services for people with hereditary angioedema.
This page was last updated: